SEC Tracker
Get the app

Drugs Made In America Acquisition DMAA

Drugs Made In America Acquisition Q2 FY25: net income $2.3M

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Drugs Made In America Acquisition reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income$2.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Cash and cash equivalents$822No year-earlier figure tagged10-Q balance sheet, on EDGAR
  3. Cash from operations−$107KNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Drugs Made In America Acquisition files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 6770 and related industry codes: the same peer list as the financial tables.

  1. Archimedes Tech SPAC Partners II ATII public float $235M, Jun 30, 2025
  2. Fifth Era Acquisition Corp I FERA public float $236M, Jun 30, 2025
  3. Sizzle Acquisition Corp. II SZZL public float $233M, Jun 30, 2025
  4. GSR IV Acquisition GSRF public float $236M, Jun 30, 2025
  5. Jena Acquisition Corp II JENA public float $236M, Jun 30, 2025